NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading TEM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
TEM represents a speculative growth investment. The current thesis state reflects uncertainty due to recent weak financial results, but there are potential upsides if the broader Healthcare sector performs well.
The market appears to have priced in a low expectations gap, indicating that investors are not overly optimistic about TEM's near-term performance. Valuation is seen as cheap compared to peers, but the fundamentals suggest fragility.
Management is focused on increasing revenue guidance and improving Adjusted EBITDA, but recent financial performance has been weak. There is a low probability of missing expectations in the near term, although recent history shows the potential for significant misses.
The long-term thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and HQY. If these companies continue to perform well, it could support TEM's growth. Conversely, if they start missing expectations, it could negatively impact TEM.
In the next 1-3 years, TEM's trajectory will depend heavily on sector performance and management's ability to execute on their financial goals. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Raising the revenue guidance to $1.59B-$1.60B shows strong growth. This would signal confidence in future performance.
Confirms:Management will raise revenue guidance during the earnings call on July 30, 2026.
Disproves:Management keeps or lowers the revenue guidance from the current target.
Why it matters: The earnings report will show important details about revenue and profit trends. It will affect how investors feel.
Confirms one read:Earnings report shows revenue growth exceeding 25% year over year.
Confirms the other:Earnings report shows revenue growth below 15% year over year.
Why it matters: Meeting or exceeding this figure would confirm strong demand and support the raised guidance.
Confirms:Q2 revenue reported at or above $348 million.
Disproves:Q2 revenue reported below $348 million.
Why it matters: Finishing this offering is key for funding growth and cutting debt. It affects stability.
Confirms:A press release will confirm the $460M offering is complete.
Disproves:Not finishing the offering or having big delays in the process.
Why it matters: If sector revenue growth picks up, it could benefit TEMPUS AI's performance.
Confirms one read:Health Care sector revenue growth is speeding up toward 10% or more.
Confirms the other:Sector revenue growth keeps slowing down below 10%.
Why it matters: Meeting this EBITDA target shows good operations and profits. It is key for long-term growth.
Confirms:Adjusted EBITDA will be at or above $65 million in the next earnings release.
Disproves:Adjusted EBITDA will be less than $60 million. This shows there are operational problems.
Why it matters: Earnings results will show if the company continues to grow. A beat would support the growth narrative.
Confirms one read:Earnings per share is higher than what analysts expected. This shows strong performance.
Confirms the other:Earnings per share is lower than analyst expectations. This suggests weaker growth.
Why it matters: Better Adjusted EBITDA shows progress. This means the company is making more money.
Confirms:Adjusted EBITDA is -$2.8 million or better in Q2.
Disproves:Adjusted EBITDA is worse than -$2.8 million.
Why it matters: Finishing this will give better financial options. It will also lower interest costs.
Confirms:The offering is completed and proceeds are used as planned.
Disproves:The offering fails to close or proceeds are not used as intended.
